Pharma · Skyrizi & Rinvoq (post-Humira)
AbbVie
Once facing a revenue cliff as Humira lost patent protection, AbbVie rebounded with successor immunology drugs Skyrizi and Rinvoq. FY2025 net revenues hit a record $61.2 billion, and the two drugs together brought in $25.9 billion, surpassing Humira's peak. Neuroscience (Vraylar, Botox), oncology (Imbruvica, Venclexta) and aesthetics round out the mix.
ABBV Updated Sep 11, 2026 2 AI consumers· 2 recurring
Per the valuechain.wiki graph, AbbVie is directly linked to 3 companies (0 supply, 3 revenue relationships) and reaches 4 companies within two hops; the links are backed by 6 dated sources, 3 of them primary filings (as of 2026-09-11).
Financials & Segments
- Total revenue · $61.2B (FY2025)
- Segments · Immunology (Skyrizi, Rinvoq, Humira) · Neuroscience (Vraylar, Botox, Ubrelvy) · Oncology (Imbruvica, Venclexta, Elahere) · Aesthetics (Botox Cosmetic, Juvederm)
Revenue from
- Immunology market (Skyrizi, Rinvoq) High confidence· Amount $25.9B · FY2025 스카이리치+린버크 · Skyrizi $17.56B, Rinvoq $8.30B, Humira $4.54B
Top revenue driver. Skyrizi $17.6B (+50%) and Rinvoq $8.3B (+39%) together reached $25.9B, offsetting Humira's fall to $4.5B (-49%) under direct biosimilar competition and lifting total revenue to a record $61.2B. - Neuroscience & aesthetics market (Botox, Vraylar, Ubrelvy) High confidence· Amount $3.8B · FY2025 Botox Therapeutic · Vraylar $3.62B, Botox Ther. $3.77B, Ubrelvy $1.27B, Botox Cosmetic $2.60B
Second growth pillar after immunology. Vraylar $3.6B (+11%), Botox Therapeutic $3.8B (+15%), Ubrelvy $1.3B (+27%) and Qulipta $1.0B (+57%), plus aesthetic Botox Cosmetic $2.6B. - Cencora, Inc. High confidence
AbbVie sells medicines to Cencora, a major U.S. wholesale customer, and said that three wholesalers including Cencora represented substantially all of its FY2025 U.S. pharmaceutical sales, but did not disclose Cencora's individual amount. - Cardinal Health, Inc. High confidence
AbbVie sells its U.S. pharmaceutical products through major wholesalers including Cardinal Health and does not disclose the amount or share attributable specifically to Cardinal Health. - Celltrion Medium confidence· Amount $4.5B · FY2025 Humira · Humira 2023 $14.4B to 2025 $4.5B (-49% YoY)
Celltrion's Humira biosimilar Yuflyma entered the U.S. under a patent settlement with AbbVie (royalty-bearing license). Biosimilar competition drove Humira revenue from $14.4B in 2023 to $4.5B in 2025. - Oncology market (Imbruvica, Venclexta, Elahere) Medium confidence· Amount $2.9B · FY2025 Imbruvica · Imbruvica $2.87B, Venclexta $2.79B
Imbruvica $2.9B (-14%, intensifying BTK competition) and Venclexta $2.8B (+8%) anchor oncology, with Elahere (ovarian-cancer ADC, acquired 2024) added as a new growth driver.
Pays to
- API & contract manufacturing (CDMO) supply chain High confidence· Amount $18.2B · FY2025 Cost of products sold · Cost of products sold $18,204M
Cost of products sold $18.2B. AbbVie sources raw materials from numerous global suppliers and contracts third parties for API, product manufacturing, fill/finish and packaging, avoiding single-source dependence with alternate supply relationships. - R&D and licensed-in IPR&D High confidence· Amount $9.1B · FY2025 R&D · R&D $9,096M; Acquired IPR&D $5,016M
R&D expense $9.1B plus acquired IPR&D and milestones $5.0B make pipeline investment the largest cost axis, defending post-Humira growth through in-licensing/acquisitions (e.g., Elahere) and internal R&D.
Value-chain ripple (2 tiers)
Following node-to-node links up to 2 tiers; each firm is shown once, at its nearest tier.
| Company | Chain | '21 | '22 | '23 | '24 | '25 | YTD |
|---|---|---|---|---|---|---|---|
| CVS Health | lead2 | +54.9 | -7.6 | -12.5 | -40.8 | +84.3 | +24.7 |
| Cardinal Health, Inc. | lead1 | -0.4 | +54.1 | +34.1 | +19 | +76.3 | +21.1 |
| Cencora, Inc. | lead1 | +44.1 | +26.3 | +25.3 | +10.4 | +51.5 | -1.4 |
| Celltrion | lead1 | -52.3 | +13 | +10.1 | +5.4 | +22 | -5.9 |
| AbbVie | node | +32.4 | +24 | -0.2 | +18.9 | +33.1 | +14.9 |
YTD as of 2026-09-04 · source: Yahoo Finance
AbbVie operates across S&P 500, Pharma, Skyrizi & Rinvoq (post-Humira). It is +14.9% in 2026. The stock (+14.9%) and its demand side (avg -5.9%) are moving in step. Neuroscience (Vraylar, Botox), oncology (Imbruvica, Venclexta) and aesthetics round out the mix.
Analysis generated from returns as of 2026-09-04